PedAM
Pediatric Disease Annotations & Medicines
| Disease | diarrhea |
| Phenotype | C0149925|small cell lung cancer |
| Sentences | 1 |
| PubMedID- 24669240 | Phase ii studies showed that the objective response rates achieved after gefitinib treatment were between 10 and 20%, with minimal toxicities; mainly an acne-like rash and mild diarrhea, in patients with recurrent non-small cell lung cancer (the ideal trials) (3). |
Page: 1